GNFT

4.05

4.65% 0.18

アフターアワーズ： 3.82 -0.23 -5.68%

Genfit Adr (GNFT)

概要ニュース株価時系列ディスカッション予測

前日終値:

$3.87

開ける：

24時間の取引高:

14,369

Relative Volume:

2.33

時価総額：

$202.51M

収益：

当期純損益:

株価収益率:

-5.517

EPS:

-0.7341

ネットキャッシュフロー:

1週間パフォーマンス:

-3.57%

1か月パフォーマンス:

-0.70%

6か月パフォーマンス:

-5.33%

1年パフォーマンス:

-29.69%

1日の値動き範囲:

$3.82

$4.07

1週間の範囲:

$3.645

$4.24

52週間の値動き範囲:

$2.55

$5.8988

Genfit Adr Stock (GNFT) Company Profile

名前

Genfit Adr

セクター

Healthcare (1135)

産業

Biotechnology (635)

電話

住所

職員

125

Twitter

@genfit_pharma

次回の収益日

2025-09-22

最新のSEC提出書

GNFT's Discussions on Twitter

GNFT を他の銘柄と比較する

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
GNFT Genfit Adr	4.05	193.51M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	421.67	109.22B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	628.00	67.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	423.47	57.35B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	831.48	50.87B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	182.77	39.72B	447.02M	-1.18B	-868.57M	-6.1812

Genfit Adr Stock (GNFT) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2025-08-19	再開されました	H.C. Wainwright	Buy
2021-12-20	アップグレード	H.C. Wainwright	Neutral → Buy
2020-07-23	アップグレード	Stifel	Hold → Buy
2020-06-25	開始されました	BofA/Merrill	Underperform
2020-05-13	ダウングレード	Kepler	Buy → Reduce
2020-05-12	ダウングレード	Barclays	Overweight → Equal Weight
2020-05-12	ダウングレード	H.C. Wainwright	Buy → Neutral
2019-10-29	繰り返されました	B. Riley FBR	Buy
2019-06-25	開始されました	Stifel	Hold
2019-04-24	開始されました	SVB Leerink	Outperform
2019-04-22	開始されました	Barclays	Overweight

すべてを表示

Genfit Adr (GNFT) 最新ニュース

Sep 29, 2025

GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World

Sep 25, 2025

Sep 24, 2025

HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat

Sep 24, 2025

Sep 11, 2025

European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize

Sep 11, 2025

Aug 20, 2025

GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World

Aug 20, 2025

Aug 15, 2025

European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest

Aug 15, 2025

Jul 22, 2025

European ADRs Tick Up As Pharma And Telecom Lead Gains - Finimize

Jul 22, 2025

Jul 10, 2025

GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World

Jul 10, 2025

Jun 30, 2025

European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest

Jun 30, 2025

Jun 27, 2025

European Biopharma Leads Gains In ADR Market Surge - Finimize

Jun 27, 2025

European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest

Jun 27, 2025

May 31, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

May 31, 2025

May 22, 2025

European ADRs Show Optimism As Genfit Leads Gains - Finimize

May 22, 2025

May 07, 2025

European ADRs See Mixed Results With Modest Gains - Finimize

May 07, 2025

Apr 08, 2025

European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize

Apr 08, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView

Apr 08, 2025

Mar 26, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView

Mar 26, 2025

Mar 24, 2025

European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView

Mar 24, 2025

Feb 28, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView

Feb 28, 2025

Jun 10, 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire

Jun 10, 2024

Apr 07, 2024

symbol__ Stock Quote Price and Forecast - CNN

Apr 07, 2024

Dec 07, 2023

Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire

Dec 07, 2023

Nov 13, 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of - GlobeNewswire

Nov 13, 2023

Jun 30, 2023

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen

Jun 30, 2023

Dec 17, 2021

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire

Dec 17, 2021

Apr 03, 2019

Should I buy GENFIT (GNFT) - Zacks Investment Research

Apr 03, 2019

GNFT: GENFITFull Company Report - Zacks Investment Research

Apr 03, 2019

Genfit Adr (GNFT) 財務データ

Genfit Adr (GNFT) の財務データはありません。詳細については、他の銘柄を確認してください。

収益

当期純利益

現金流量

EPS

RPRX

$37.84

1.45%

GMAB

$28.76

0.17%

INCY

$102.92

1.33%

BNTX

$104.83

0.84%

ONC

$309.19

0.86%

INSM

$182.77

1.86%

Genfit Adr (GNFT)

Genfit Adr Stock (GNFT) Company Profile

GNFT を他の銘柄と比較する

Genfit Adr Stock (GNFT) Upgrades & Downgrades

Genfit Adr (GNFT) 最新ニュース

European ADRs Start The Week With Small Gains Stateside - Finimize

FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World

FY2025 EPS Estimates for GENFIT Lifted by Leerink Partnrs - Defense World

HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat

GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World

HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat

European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize

GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World

European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest

European ADRs Tick Up As Pharma And Telecom Lead Gains - Finimize

GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World

European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest

European Biopharma Leads Gains In ADR Market Surge - Finimize

European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

European ADRs Show Optimism As Genfit Leads Gains - Finimize

European ADRs See Mixed Results With Modest Gains - Finimize

European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView

European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire

symbol__ Stock Quote Price and Forecast - CNN

Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire

Results from Ipsen’s ELATIVE® pivotal Phase III trial of - GlobeNewswire

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire

Should I buy GENFIT (GNFT) - Zacks Investment Research

GNFT: GENFITFull Company Report - Zacks Investment Research

Genfit Adr (GNFT) 財務データ

収益

当期純利益

現金流量

EPS

GNFTに似た銘柄